Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PZ Wind Down Inc PZRXQ

Healthcare Biotechnology
Pz Wind Down, Inc., formerly, PhaseRx, Inc. is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia... see more

Recent & Breaking News (GREY:PZRXQ)

PhaseRx Receives Decision from the Nasdaq Hearings Panel for Continued Listing of Shares

PR Newswire December 13, 2017

PhaseRx Commences Voluntary Chapter 11 Bankruptcy Protection Proceeding

PR Newswire December 11, 2017

Mid-Afternoon Market Update: Dow Jumps Over 150 Points; Auris Medical Shares Plummet

Benzinga.com  November 28, 2017

Mid-Day Market Update: Thor Industries Surges On Earnings Beat; Momo Shares Plunge

Benzinga.com  November 28, 2017

Mid-Morning Market Update: Markets Open Higher; Arby's To Merge With Buffalo Wild Wings

Benzinga.com  November 28, 2017

PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from European Medicines Agency

PR Newswire November 28, 2017

PhaseRx Reports Third Quarter 2017 Financial Results and Provides Corporate Update

PR Newswire November 9, 2017

Analysis: Positioning to Benefit within Tandem Diabetes Care, CASI Pharmaceuticals, SAExploration, Roka Bioscience, VirnetX, and PhaseRx – Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire November 2, 2017

PhaseRx to Present at 5th International mRNA Conference

PR Newswire October 31, 2017

PhaseRx Receives Delisting Notice from Nasdaq and Evaluates Listing Options

PR Newswire October 26, 2017

Mid-Afternoon Market Update: Applied Optoelectronics Drops On Q3 Warning; PhaseRx Shares Surge

Benzinga.com  October 13, 2017

Mid-Day Market Update: Crude Oil Up Over 1%; Tandem Diabetes Care Shares Plunge

Benzinga.com  October 13, 2017

PhaseRx Announces Corporate Restructuring and Review of Strategic Alternatives

PR Newswire October 13, 2017

PhaseRx Receives Orphan Drug Designation from FDA for PRX-ASL for the Treatment of Argininosuccinate Lyase Deficiency

PR Newswire September 20, 2017

PhaseRx Reports First Quarter 2017 Financial Results and Provides Corporate Update

PR Newswire May 12, 2017

PhaseRx to Present Data at the American Society of Gene & Cell Therapy 20th Annual Meeting

PR Newswire May 3, 2017

PhaseRx to Present Data at the TIDES Conference

PR Newswire April 27, 2017

PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-OTC from European Medicines Agency

PR Newswire Europe Non Regulatory April 25, 2017

PhaseRx Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

PR Newswire March 27, 2017

Research Reports Initiation on Biotech Stocks -- Radius Health, Acorda, PhaseRx, and Athersys

PR Newswire March 22, 2017